AXA (CSP) Q4 2025 (Media) earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 (Media) earnings summary
17 Apr, 2026Executive summary
Achieved record financial results in FY25, with revenues of €116 billion (+6%), underlying earnings of €8.4 billion (+6%), and underlying EPS of €3.86 (+8%), driven by strong growth across all business lines and geographies.
Net income rose 26% to €9.8 billion, benefiting from higher underlying earnings and the gain from the AXA IM sale.
Solvency II ratio improved to 224%, reflecting robust capital generation and prudent reserve management.
Laying foundations for the next strategic plan with a focus on technology, AI, and capital allocation.
Financial highlights
Revenues/premiums grew 6% year-over-year to €116 billion; underlying earnings €8.4 billion (+6%); net income €9.8 billion (+26%).
Underlying EPS: €3.86 (+8%); underlying ROE: 16.0%.
Dividend proposed at €2.32 per share (+8%) and new annual share buyback program up to €1.25 billion.
Debt gearing at 22.3%.
Solvency II ratio: 224% (+9pts), expected to adjust to 215% in 2026 due to regulatory changes.
Outlook and guidance
Confident in achieving the high end of the 6–8% underlying EPS growth target for 2026.
Solvency II revision expected to add +17 points to the ratio in 2027.
Next strategic plan for 2027–2029 to be presented in September 2026.
Guidance maintained for underlying ROE between 14–16% and cumulative organic cash upstream >€21 billion for 2024–2026.
Latest events from AXA
- 7% revenue growth, strong capital, and major strategic moves drive robust 1H24 performance.CSP
Q2 20249 Jul 2026 - Revenue and premiums up 7%, earnings up 6%, Solvency II ratio at 220%, ROE 17.5%.CSP
Q2 2025 (Media)8 Jul 2026 - 7% revenue growth and a 221% solvency ratio support the 2024 EPS target of 6%-8%.CSP
Q3 20248 Jul 2026 - 8% revenue and EPS growth, record profits, and 9% higher dividend drive strong returns.CSP
Q4 20248 Jul 2026 - Record earnings, strong capital, and robust growth across core segments in FY25.CSP
Q4 20258 Jul 2026 - 6% revenue growth, strong P&C and Life & Health, Solvency II at 211%, AA rating upgrade.CSP
Q1 20268 May 2026 - Record earnings, dividend hike, and strategic focus on AI and resilience were approved.CSP
AGM 202630 Apr 2026 - Strong growth, AI-driven efficiency, and disciplined capital management underpin a positive outlook.CSP
Morgan Stanley European Financials Conference 202617 Mar 2026 - Record growth, €2.15 dividend, digital innovation, and climate action drive strong results.CSP
AGM 20253 Feb 2026